Opsona Therapeutics
DUBLIN, May 6, 2011 - Opsona Therapeutics, a drug development company focused on novel
therapeutic approaches to treat autoimmune and inflammatory diseases
announced that it will receive EUR5.9million, one of the largest grants ever
awarded by the European Union FP7 Health, Program, to lead a European
consortium of research and clinical groups (MABSOT*) in the advancement of
clinical trials for its lead drug candidate OPN-305 in solid organ
transplantation.